Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
In a challenging year for biotechnology firms, Amicus Therapeutics (NASDAQ:FOLD) stock has touched a 52-week low of $8.54, despite showing impressive gross profit margins of 90% and strong revenue growth of 32% over the past year. The company, which specializes in therapies for rare and orphan diseases, has seen its shares retreat significantly, down about 24% over the past year. According to InvestingPro analysis, the stock appears slightly undervalued at current levels. Investors have been cautious as the sector faces headwinds from regulatory hurdles and a shifting healthcare market. Amicus Therapeutics, despite its innovative pipeline and strong liquidity position with a current ratio of 3.39, has not been immune to these pressures, reflecting the broader industry trend in its recent stock performance. InvestingPro has identified 12 additional investment tips for Amicus Therapeutics, available in the comprehensive Pro Research Report.
In other recent news, Amicus Therapeutics announced its full-year 2024 total revenue of $528.3 million, reflecting a 33% increase year-over-year. The growth was driven primarily by Galafold sales, which reached $458.2 million, a 19% rise from the previous year, while Pombiliti+Opfolda contributed $70.2 million. The company has projected Galafold revenue to grow by 10%-15% in 2025, translating to $504 million to $527 million. Additionally, Pombiliti+Opfolda revenue is expected to increase by 65%-85%, equating to $116 million to $130 million.
Amicus Therapeutics has filed a prospectus supplement to register unsold shares under its at-the-market program, ensuring flexibility for future share sales. Analyst actions include BofA Securities lowering its price target for Amicus to $14 but maintaining a Buy rating, while Goldman Sachs reiterated a Neutral rating with a $14 price target. Jefferies analysts maintain a Buy rating with a price target of $18, noting the company’s conservative stance on Pompe disease treatments. These developments highlight Amicus Therapeutics’ strategic approach to managing expectations and its potential for consistent performance improvements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.